Are chimeric antigen receptor T cells (CAR-T cells) the long run in immunotherapy for autoimmune illnesses?
Goal: CAR-T cell remedy has revolutionized the remedy of oncological illnesses, and potential makes use of in autoimmune illnesses have just lately been described. The overview goals to combine the accessible knowledge on remedy with CAR-T cells, emphasizing autoimmune illnesses, to find out therapeutic advances and their doable future medical applicability in autoimmunity.
Supplies and strategies: A search was carried out in PubMed with the key phrases “Chimeric Antigen Receptor” and “CART cell”. The paperwork of curiosity have been chosen, and a essential overview of the data was carried out.
Outcomes: Within the remedy of autoimmune illnesses, in preclinical fashions, three completely different mobile methods have been used, which embody Chimeric antigen receptor T cells, Chimeric autoantibody receptor T cells, and Chimeric antigen receptor in regulatory T lymphocytes. All three sorts of remedy have been efficient. The potential antagonistic results inside them, cytokine launch syndrome, mobile toxicity and neurotoxicity should all the time be stored in thoughts.
Conclusions: Though info in people just isn’t but accessible, preclinical fashions of CAR-T cells within the remedy of autoimmune illnesses present promising outcomes, in order that sooner or later, they could turn out to be a helpful and efficient remedy within the remedy of those pathologies.
Ovalbumin Antigen-Particular Activation of Human T Cell Receptor Carefully Resembles Soluble Antibody Stimulation as Revealed by BOOST Phosphotyrosine Proteomics
Activation of the T cell receptor (TCR) results in a community of early signaling predominantly orchestrated by tyrosine phosphorylation in T cells. The TCR is usually activated utilizing soluble anti-TCR antibodies, however this method just isn’t antigen-specific. Alternatively, activating the TCR utilizing particular antigens of a spread of binding affinities within the type of a peptide-major histocompatibility advanced (pMHC) is presumed to be extra physiological. Nonetheless, because of the lack of wide-scale phosphotyrosine (pTyr) proteomic research straight evaluating anti-TCR antibodies and pMHC, a complete definition of those activated states stays enigmatic.
Elucidation of the tyrosine phosphoproteome utilizing quantitative pTyr proteomics permits a greater understanding of the distinctive options of those activating brokers and the position of ligand binding affinity on signaling. Right here, we apply the just lately established Broad-spectrum Optimization Of Selective Triggering (BOOST) to look at perturbations in tyrosine phosphorylation of human TCR triggered by anti-TCR antibodies and pMHC. Our knowledge reveal that high-affinity ovalbumin (OVA) pMHC activation of the human TCR triggers a largely related, albeit doubtlessly stronger, pTyr-mediated signaling regulatory axis in comparison with the anti-TCR antibody. The signaling output ensuing from OVA pMHC variants correlates properly with their weaker affinities, enabling affinity-tunable management of signaling energy. Collectively, we offer a framework for making use of BOOST to match pTyr-mediated signaling pathways of human T cells activated in an antigen-independent and antigen-specific method.
Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell remedy for a myeloma affected person
Chimeric antigen receptor T (CAR-T)-cell remedy is a promising remedy for relapsed/refractory a number of myeloma (RRMM). In our earlier report, CD19- and BCMA-targeted CAR-T co-administration was related to a excessive response fee. Though cytokine launch syndrome (CRS) and neurotoxicity are frequent issues following CAR-T remedy, cerebral infarction is never reported as a CAR-T-related complication. We reported a 73-year-old feminine MM affected person who obtained CD19- and BCMA-targeted CAR-T for refractory illness.
Her illness responded to CAR-T remedy, however she developed neurological signs following CRS. Cranial CT and MRI demonstrated a number of cerebral infarctions and bilateral anterior cerebral artery (ACA) occlusion. We propose that cerebral infarction aside from CAR-T-related neurotoxicity is the underlying reason behind irregular neuropsychological signs, and diagnostic imaging assessments must be actively carried out to exclude ischemic cerebrovascular occasions.
CMV Control lentiviral particles (Neo) |
|||
| CMV-Null-Neo | GenTarget | 1 x107 IFU/ml x 200ul | EUR 349 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the Neomycin marker under RSV promoter. |
|||
CMV Control lentiviral particles (Puro) |
|||
| CMV-Null-Puro | GenTarget | 1 x107 IFU/ml x 200ul | EUR 349 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the Puromycin marker under RSV promoter. |
|||
EBAG9 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV694975 | ABM | 1.0 ug DNA | EUR 514 |
CMV Control lentiviral particles (GFP-Bsd) |
|||
| CMV-Null-GB | GenTarget | 1 x107 IFU/ml x 200ul | EUR 349 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the GFP-Blasticidin fusion marker under RSV promoter. |
|||
CMV Control lentiviral particles (GFP-Puro) |
|||
| CMV-Null-GP | GenTarget | 1 x107 IFU/ml x 200ul | EUR 349 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the GFP-Puromycin fusion marker under RSV promoter. |
|||
CMV Control lentiviral particles (RFP-Bsd) |
|||
| CMV-Null-RB | GenTarget | 1 x107 IFU/ml x 200ul | EUR 349 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the RFP-Blasticidin fusion marker under RSV promoter. |
|||
CMV Control lentiviral particles (RFP-Puro) |
|||
| CMV-Null-RP | GenTarget | 1 x107 IFU/ml x 200ul | EUR 349 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the RFP-Puromycin fusion marker under RSV promoter. |
|||
CMV control lentivirus (Hygro) |
|||
| CMV-Null-Hygro | GenTarget | 1 x107 IFU/ml x 200ul | EUR 349 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It has the hygromycin selection under RSV promoter. |
|||
CMV control lentivirus (Zeo) |
|||
| CMV-Null-Zeo | GenTarget | 1 x107 IFU/ml x 200ul | EUR 349 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It has the Zeocin selection under RSV promoter. |
|||
EBAG9 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV709564 | ABM | 1.0 ug DNA | EUR 316 |
EBAG9 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV709565 | ABM | 1.0 ug DNA | EUR 374 |
EBAG9 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV709566 | ABM | 1.0 ug DNA | EUR 374 |
EBAG9 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV694976 | ABM | 1.0 ug DNA | EUR 514 |
EBAG9 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV694977 | ABM | 1.0 ug DNA | EUR 572 |
EBAG9 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV694978 | ABM | 1.0 ug DNA | EUR 572 |
CMV Control lentiviral particles (Bsd) in PBS |
|||
| CMV-Null-Bsd-PBS | GenTarget | 1 x108 IFU/ml x 200ul | EUR 710 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the blasticidin marker under RSV promoter. The virus was concentrated and provided in PBS solution. |
|||
CMV Control lentiviral particles (Neo) in PBS |
|||
| CMV-Null-Neo-PBS | GenTarget | 1 x108 IFU/ml x 200ul | EUR 710 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the Neomycin marker under RSV promoter. The virus was concentrated and provided in PBS solution. |
|||
CMV Control lentiviral particles (Puro) in PBS |
|||
| CMV-Null-Puro-PBS | GenTarget | 1 x108 IFU/ml x 200ul | EUR 710 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the Puromycin marker under RSV promoter. The virus was concentrated and provided in PBS solution. |
|||
CMV Control lentiviral particles (GFP-Bsd) in PBS |
|||
| CMV-Null-GB-PBS | GenTarget | 1 x108 IFU/ml x 200ul | EUR 710 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the GFP-Blasticidin fusion marker under RSV promoter. The virus was concentrated and provided in PBS solution. |
|||
CMV Control lentiviral particles (GFP-Puro) in PBS |
|||
| CMV-Null-GP-PBS | GenTarget | 1 x108 IFU/ml x 200ul | EUR 710 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the GFP-Puromycin fusion marker under RSV promoter. The virus was concentrated and provided in PBS solution. |
|||
CMV Control lentiviral particles (RFP-Bsd) in PBS |
|||
| CMV-Null-RB-PBS | GenTarget | 1 x108 IFU/ml x 200ul | EUR 710 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the RFP-Blasticidin fusion marker under RSV promoter. The virus was concentrated and provided in PBS solution. |
|||
CMV Control lentiviral particles (RFP-Puro) in PBS |
|||
| CMV-Null-RP-PBS | GenTarget | 1 x108 IFU/ml x 200ul | EUR 710 |
|
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the RFP-Puromycin fusion marker under RSV promoter. The virus was concentrated and provided in PBS solution. |
|||
EBAG9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV709567 | ABM | 1.0 ug DNA | EUR 316 |
EBAG9 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV709568 | ABM | 1.0 ug DNA | EUR 316 |
HPC1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728669 | ABM | 1.0 ug DNA | Ask for price |
HPCX Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728675 | ABM | 1.0 ug DNA | Ask for price |
HPE1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728681 | ABM | 1.0 ug DNA | Ask for price |
HPFH2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728687 | ABM | 1.0 ug DNA | Ask for price |
HPLH1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728693 | ABM | 1.0 ug DNA | Ask for price |
HPP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728699 | ABM | 1.0 ug DNA | Ask for price |
HPRTP2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728705 | ABM | 1.0 ug DNA | Ask for price |
HPRTP3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728711 | ABM | 1.0 ug DNA | Ask for price |
HPRTP4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728717 | ABM | 1.0 ug DNA | Ask for price |
HPT Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728723 | ABM | 1.0 ug DNA | Ask for price |
HPV6AI1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728729 | ABM | 1.0 ug DNA | Ask for price |
HPV18I1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728735 | ABM | 1.0 ug DNA | Ask for price |
HPV18I2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728741 | ABM | 1.0 ug DNA | Ask for price |
HRES1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728747 | ABM | 1.0 ug DNA | Ask for price |
HRPT1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728753 | ABM | 1.0 ug DNA | Ask for price |
HSBP1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728771 | ABM | 1.0 ug DNA | Ask for price |
HSD3BP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728777 | ABM | 1.0 ug DNA | Ask for price |
HSD3BP2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728783 | ABM | 1.0 ug DNA | Ask for price |
HSD3BP3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728789 | ABM | 1.0 ug DNA | Ask for price |
HSD3BP4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728795 | ABM | 1.0 ug DNA | Ask for price |
HSD3BP5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728801 | ABM | 1.0 ug DNA | Ask for price |
HSFX2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728807 | ABM | 1.0 ug DNA | Ask for price |
HSFY4P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728813 | ABM | 1.0 ug DNA | Ask for price |
HSFY5P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728819 | ABM | 1.0 ug DNA | Ask for price |
HSFY6P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728825 | ABM | 1.0 ug DNA | Ask for price |
HSFY7P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728831 | ABM | 1.0 ug DNA | Ask for price |
HSFY8P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728837 | ABM | 1.0 ug DNA | Ask for price |
HSP90AA5P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728843 | ABM | 1.0 ug DNA | Ask for price |
HSP90AA6P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728849 | ABM | 1.0 ug DNA | Ask for price |
HSP90AB5P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728855 | ABM | 1.0 ug DNA | Ask for price |
HSP90AB6P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728861 | ABM | 1.0 ug DNA | EUR 1790 |
HSPA8P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728867 | ABM | 1.0 ug DNA | Ask for price |
HSPA9P2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728873 | ABM | 1.0 ug DNA | Ask for price |
HSPD1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728879 | ABM | 1.0 ug DNA | Ask for price |
HSPD1P2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728885 | ABM | 1.0 ug DNA | Ask for price |
HSPD1P3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728891 | ABM | 1.0 ug DNA | Ask for price |
HSPD1P4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728897 | ABM | 1.0 ug DNA | Ask for price |
HSPD1P7 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728903 | ABM | 1.0 ug DNA | Ask for price |
HSPD1P8 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728909 | ABM | 1.0 ug DNA | Ask for price |
HSPD1P9 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728915 | ABM | 1.0 ug DNA | EUR 1790 |
HSPD1P10 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728921 | ABM | 1.0 ug DNA | Ask for price |
HSPD1P12 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728927 | ABM | 1.0 ug DNA | Ask for price |
HSPD1P15 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728933 | ABM | 1.0 ug DNA | Ask for price |
HSPE1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728939 | ABM | 1.0 ug DNA | Ask for price |
HSPE1P2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728945 | ABM | 1.0 ug DNA | Ask for price |
HTATSF1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728951 | ABM | 1.0 ug DNA | Ask for price |
HTC1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728957 | ABM | 1.0 ug DNA | Ask for price |
HTC2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728963 | ABM | 1.0 ug DNA | Ask for price |
HTL Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728969 | ABM | 1.0 ug DNA | Ask for price |
HTLVR Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728975 | ABM | 1.0 ug DNA | Ask for price |
HTOR Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV728981 | ABM | 1.0 ug DNA | Ask for price |
HTX2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729017 | ABM | 1.0 ug DNA | Ask for price |
HV1S Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729023 | ABM | 1.0 ug DNA | Ask for price |
HVBS7 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729029 | ABM | 1.0 ug DNA | Ask for price |
HVBS8 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729035 | ABM | 1.0 ug DNA | Ask for price |
HYD2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729041 | ABM | 1.0 ug DNA | Ask for price |
IBD2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729053 | ABM | 1.0 ug DNA | Ask for price |
IBD3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729059 | ABM | 1.0 ug DNA | Ask for price |
IBD4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729065 | ABM | 1.0 ug DNA | Ask for price |
IBD5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729071 | ABM | 1.0 ug DNA | Ask for price |
IBD6 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729077 | ABM | 1.0 ug DNA | Ask for price |
IBD7 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729083 | ABM | 1.0 ug DNA | Ask for price |
IBD8 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729089 | ABM | 1.0 ug DNA | Ask for price |
IBD9 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729095 | ABM | 1.0 ug DNA | Ask for price |
IBGC1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729101 | ABM | 1.0 ug DNA | Ask for price |
IBM3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729107 | ABM | 1.0 ug DNA | Ask for price |
IBTKP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729113 | ABM | 1.0 ug DNA | Ask for price |
ICCA Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729119 | ABM | 1.0 ug DNA | Ask for price |
ICR1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729125 | ABM | 1.0 ug DNA | Ask for price |
ICR3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729131 | ABM | 1.0 ug DNA | Ask for price |
ICR4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729137 | ABM | 1.0 ug DNA | Ask for price |
ICR5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729143 | ABM | 1.0 ug DNA | Ask for price |
ICS1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729149 | ABM | 1.0 ug DNA | Ask for price |
IDDM2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV729155 | ABM | 1.0 ug DNA | Ask for price |
The Intracellular Area of CD40 is a Potent Costimulatory Component in Chimeric Antigen Receptors
The costimulatory domains included into second-generation and third-generation chimeric antigen receptors (CARs) strongly affect CAR-T-cell operate. Right here, we explored second-generation and third-generation CARs harboring the signaling area of the CD40 receptor as a brand new costimulatory aspect as compared with related CARs carrying the 4-1BB area. In CARs of each generations, CD40 was stronger than 4-1BB in triggering the NF-κB signaling pathway.
In human T cells from 2 donors, CD40 was akin to 4-1BB in upregulating costimulatory and activation markers, inducing proinflammatory cytokine secretion and mediating goal cell killing. Apparently, variations within the response sample of T cells from the two donors with respect to CD40 and 4-1BB have been evident. We conclude that in human T cells, the CD40 signaling area is a potent costimulatory aspect in each second-generation and third-generation CARs.
A Systematic Overview of the Function of Chimeric Antigen Receptor T (CAR-T) Cell Remedy within the Therapy of Strong Tumors
Chimeric antigen receptor T (CAR-T) cell remedy makes use of sufferers’ personal T lymphocytes which might be engineered to assault most cancers cells. It’s Meals and Drug Administration (FDA)-approved in numerous hematological malignancies and presently being evaluated in strong cancers in early section research. We did a scientific overview consisting of 15 potential medical trials (n=159) evaluating CAR-T cells in strong cancers. Early section trials confirmed promising response charges in ovarian epithelial most cancers (100%), human epidermal progress issue receptor 2 (HER2)-positive sarcoma (67%), epidermal progress issue receptor (EGFR)-positive biliary tract most cancers (65%), superior gastric/pancreatic most cancers (82%), hepatocellular carcinoma (67%), and colorectal most cancers (70%).
The median general response throughout all malignancies was 62% (vary 17%-100%). Median progression-free survival and general survival weren’t reached in most trials. Cytokine launch syndrome was seen in just one affected person with cholangiocarcinoma who obtained EGFR-specific CAR-T cell remedy. Though survival knowledge continues to be not mature, CAR-T cell remedy in strong malignancies did present encouraging response charges and was well-tolerated.
Variations in lymphoma sufferers between chimeric antigen receptor T-cell remedy trials and the overall inhabitants
Chimeric antigen receptor (CAR)-T cell therapies seem to be promising therapies for non-Hodgkin’s and B-cell lymphoma. Nonetheless, a number of CAR-T therapies accredited by the US Meals and Drug Administration have solely been examined for efficacy in comparatively few single-arm medical trials with small pattern sizes. We sought to look at the variations between sufferers in these trials and the overall inhabitants of sufferers with non-Hodgkin’s and B-cell lymphoma. 5 hundred and twenty-two sufferers from 15 CAR-T trials present in a scientific overview and 417,492 sufferers from the Surveillance, Epidemiology, and Finish Outcomes (SEER) Program database have been in contrast.
CAR-T research individuals seemed to be youthful (46.7% beneath 70 years previous vs. 42.2%), extra male (68.0% vs. 55.7%), and adopted for a shorter time period in comparison with sufferers within the SEER inhabitants (imply [M] 45.6 months, 95% confidence interval [CI] 17.7 to 63.three months follow-up vs. M 57.1 months, 95% CI 57.Zero to 57.three months survival). CAR-T research individuals might differ considerably from the overall inhabitants of sufferers with non-Hodgkin’s and B-cell lymphoma. Effectiveness of CAR-T therapies within the common inhabitants of lymphoma sufferers might differ from effectiveness demonstrated in trials. Newly created CAR-T affected person registries are important to establishing population-level effectiveness of the therapies.
Recombinant Human ITGB1 Protein, His, E.coli-2ug |
|||
| QP12462-HIS-2ug | EnQuireBio | 2ug | EUR 155 |
Recombinant Human ITGB1 Protein, His, E.coli-5ug |
|||
| QP12462-HIS-5ug | EnQuireBio | 5ug | EUR 155 |
Recombinant Human ITGB1 Protein, His, E.coli-1mg |
|||
| QP12462-HIS-EC-1mg | EnQuireBio | 1mg | EUR 2757 |
ITGB1 protein (His tag) |
|||
| 80R-3617 | Fitzgerald | 100 ug | EUR 327 |
|
Description: Purified recombinant ITGB1 protein (His tag) |
|||
Human Integrin Beta 1 (ITGb1) ELISA Kit |
|||
| RD-ITGb1-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 500 |
Human Integrin Beta 1 (ITGb1) ELISA Kit |
|||
| RD-ITGb1-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 692 |
Human Integrin Beta 1 (ITGb1) ELISA Kit |
|||
| DLR-ITGb1-Hu-48T | DL Develop | 48T | EUR 498 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Integrin Beta 1 (ITGb1) in samples from tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Human Integrin Beta 1 (ITGb1) ELISA Kit |
|||
| DLR-ITGb1-Hu-96T | DL Develop | 96T | EUR 647 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Integrin Beta 1 (ITGb1) in samples from tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Human Integrin Beta 1 (ITGb1) ELISA Kit |
|||
| RDR-ITGb1-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 522 |
Human Integrin Beta 1 (ITGb1) ELISA Kit |
|||
| RDR-ITGb1-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 724 |
XMIR-21 RNA oligo miRNA-21-5p with Xmotif |
|||
| XMIR-21 | SBI | 10 rxn | EUR 438 |
Recombinant Human ITGB1 Protein, His, Insect-1mg |
|||
| QP12462-HIS-INSECT-1mg | EnQuireBio | 1mg | EUR 5251 |
AXMIR-21 RNA oligo anti-miRNA-21-5p with Xmotif |
|||
| AXMIR-21 | SBI | 10 reactions | EUR 438 |
Recombinant (E.coli) Human CD40 (aa: 21-193, His Tag, >95% Pure) |
|||
| HCD4015-N-10 | Alpha Diagnostics | 10 ug | EUR 286 |
FGF-21 Fibroblast Growth Factor-21 Human Recombinant Protein, His Tag |
|||
| PROTQ9NSA1 | BosterBio | Regular: 50ug | EUR 317 |
|
Description: Fibroblast Growth Factor -21 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 202 amino acids (29-209) and having a molecular mass of 21.6 kDa (molecular weight on SDS-PAGE will appear higher). ;The FGF-21 is fused to a 20 amino acid His Tag at N-terminus and purified by proprietary chromatographic techniques. |
|||
XMIRXpress lentivector miRNA-21-5p with Xmotif |
|||
| XMIRXP-21 | SBI | 10 ug | EUR 677 |
Recombinant Human Fibroblast Growth Factor-21, His Tag |
|||
| 7-00385 | CHI Scientific | 10µg | Ask for price |
Recombinant Human Fibroblast Growth Factor-21, His Tag |
|||
| 7-00386 | CHI Scientific | 50µg | Ask for price |
Recombinant Human Fibroblast Growth Factor-21, His Tag |
|||
| 7-00387 | CHI Scientific | 1mg | Ask for price |
Recombinant (E.coli) Rat CD40 (aa: 21-193, His Tag, >95% Pure) |
|||
| RCD4015-N-10 | Alpha Diagnostics | 10 ug | EUR 213 |
Recombinant (E.Coli, His-tag) Human Syndecan-4, His-tag |
|||
| RP-993 | Alpha Diagnostics | 10 ug | EUR 225 |
Human ITGA1&ITGB1 Heterodimer Protein (Phe 29-Pro 1141 (ITGA1)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1839Lsx-100g | Creative Biolabs | 100 µg | EUR 1178 |
|
Description: Human ITGA1&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P56199-1 (ITGA1)&P05556-1 (ITGB1)) |
|||
Human ITGA1&ITGB1 Heterodimer Protein (Phe 29-Pro 1141 (ITGA1)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1839Lsx-1mg | Creative Biolabs | 1 mg | EUR 7969 |
|
Description: Human ITGA1&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P56199-1 (ITGA1)&P05556-1 (ITGB1)) |
|||
Human ITGA10&ITGB1 Heterodimer Protein (Phe 23-Ser 1122 (ITGA10)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1840Lsx-100g | Creative Biolabs | 100 µg | EUR 1178 |
|
Description: Human ITGA10&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: O75578-1 (ITGA10)&P05556-1 (ITGB1)) |
|||
Human ITGA10&ITGB1 Heterodimer Protein (Phe 23-Ser 1122 (ITGA10)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1840Lsx-1mg | Creative Biolabs | 1 mg | EUR 7969 |
|
Description: Human ITGA10&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: O75578-1 (ITGA10)&P05556-1 (ITGB1)) |
|||
Human ITGA11&ITGB1 Heterodimer Protein (Phe 23-Ser 1122 (ITGA10)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1841Lsx-100g | Creative Biolabs | 100 µg | EUR 1178 |
|
Description: Human ITGA11&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: Q9UKX5-1 (L524R) (ITGA11)&P05556-1 (ITGB1)) |
|||
Human ITGA11&ITGB1 Heterodimer Protein (Phe 23-Ser 1122 (ITGA10)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1841Lsx-1mg | Creative Biolabs | 1 mg | EUR 7969 |
|
Description: Human ITGA11&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: Q9UKX5-1 (L524R) (ITGA11)&P05556-1 (ITGB1)) |
|||
Human ITGA4&ITGB1 Heterodimer Protein (Tyr 34-Thr 977 (ITGA4)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1842Lsx-100g | Creative Biolabs | 100 µg | EUR 1178 |
|
Description: Human ITGA4&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P13612-1 (ITGA4)&P05556-1 (ITGB1)) |
|||
Human ITGA4&ITGB1 Heterodimer Protein (Tyr 34-Thr 977 (ITGA4)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1842Lsx-1mg | Creative Biolabs | 1 mg | EUR 7969 |
|
Description: Human ITGA4&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P13612-1 (ITGA4)&P05556-1 (ITGB1)) |
|||
Human ITGA5&ITGB1 Heterodimer Protein (Phe 42-Tyr 995 (ITGA5)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1844Lsx-100g | Creative Biolabs | 100 µg | EUR 1178 |
|
Description: Human ITGA5&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P08648-1 (ITGA5)&P05556-1 (ITGB1)) |
|||
Human ITGA5&ITGB1 Heterodimer Protein (Phe 42-Tyr 995 (ITGA5)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1844Lsx-1mg | Creative Biolabs | 1 mg | EUR 7969 |
|
Description: Human ITGA5&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P08648-1 (ITGA5)&P05556-1 (ITGB1)) |
|||
Human ITGA7X2B&ITGB1 Heterodimer Protein (Phe 34-Trp 1038 (ITGA7X2B)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1846Lsx-100g | Creative Biolabs | 100 µg | EUR 1178 |
|
Description: Human ITGA7X2B&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: Q13683-7 (ITGA7X2B)&P05556-1 (ITGB1)) |
|||
Human ITGA7X2B&ITGB1 Heterodimer Protein (Phe 34-Trp 1038 (ITGA7X2B)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1846Lsx-1mg | Creative Biolabs | 1 mg | EUR 7969 |
|
Description: Human ITGA7X2B&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: Q13683-7 (ITGA7X2B)&P05556-1 (ITGB1)) |
|||
Human ITGA8&ITGB1 Heterodimer Protein (Phe 39-Leu 1012 (ITGA8)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1847Lsx-100g | Creative Biolabs | 100 µg | EUR 1178 |
|
Description: Human ITGA8&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P53708-1 (ITGA8)&P05556-1 (ITGB1)) |
|||
Human ITGA8&ITGB1 Heterodimer Protein (Phe 39-Leu 1012 (ITGA8)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1847Lsx-1mg | Creative Biolabs | 1 mg | EUR 7969 |
|
Description: Human ITGA8&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P53708-1 (ITGA8)&P05556-1 (ITGB1)) |
|||
Human ITGA9&ITGB1 Heterodimer Protein (Phe 39-Leu 1012 (ITGA8)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1848Lsx-100g | Creative Biolabs | 100 µg | EUR 1178 |
|
Description: Human ITGA9&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: Q13797-1 (ITGA9)&P05556-1 (ITGB1)) |
|||
Human ITGA9&ITGB1 Heterodimer Protein (Phe 39-Leu 1012 (ITGA8)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1848Lsx-1mg | Creative Biolabs | 1 mg | EUR 7969 |
|
Description: Human ITGA9&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: Q13797-1 (ITGA9)&P05556-1 (ITGB1)) |
|||
Human ITGAV&ITGB1 Heterodimer Protein (Phe 31-Val 992 (ITGAV)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1852Lsx-100g | Creative Biolabs | 100 µg | EUR 1178 |
|
Description: Human ITGAV&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: NP_002201.1 (ITGAV)&P05556-1 (ITGB1)) |
|||
Human ITGAV&ITGB1 Heterodimer Protein (Phe 31-Val 992 (ITGAV)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1852Lsx-200g | Creative Biolabs | 200 µg | EUR 7969 |
|
Description: Human ITGAV&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: NP_002201.1 (ITGAV)&P05556-1 (ITGB1)) |
|||
FGF-21 Fibroblast Growth Factor-21 Mouse Recombinant Protein, His Tag |
|||
| PROTQ9JJN1-1 | BosterBio | Regular: 10ug | EUR 317 |
|
Description: Fibroblast Growth Factor -21 Mouse Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 192 amino acids and having a molecular mass of 21.2 kDa. The amino acid sequence of the recombinant human FGF21 is 100% homologous to the amino acid sequence of the Mouse FGF21 without signal sequence and contains 10 a.a. His tag at N-terminal.;The FGF-21 is purified by proprietary chromatographic techniques. |
|||
Recombinant (E.Coli, His-tag) Human HTRA2 |
|||
| RP-413 | Alpha Diagnostics | 10 ug | EUR 225 |
Recombinant (E.Coli, His-tag) Human STAT1 |
|||
| RP-722 | Alpha Diagnostics | 10 ug | EUR 286 |
Recombinant (E.Coli, His-tag) Human S100b |
|||
| RP-774 | Alpha Diagnostics | 10 ug | EUR 286 |
Recombinant (E.Coli, His-tag) Human Osteocrin |
|||
| RP-868 | Alpha Diagnostics | 10 ug | EUR 286 |
Recombinant (E.Coli, His-tag) Human CD29 |
|||
| RP-915 | Alpha Diagnostics | 2 ug | EUR 347 |
Recombinant (E.Coli, His-tag) Human Geminin |
|||
| RP-989 | Alpha Diagnostics | 5 ug | EUR 164 |
Biotinylated Human ITGA4&ITGB1 Heterodimer Protein (Tyr 34-Thr 977 (ITGA4)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1621Lsx-200g | Creative Biolabs | 200 µg | EUR 3844 |
|
Description: Biotinylated Human ITGA4&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P13612-1 (ITGA4)&P05556-1 (ITGB1)) |
|||
Biotinylated Human ITGA4&ITGB1 Heterodimer Protein (Tyr 34-Thr 977 (ITGA4)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1621Lsx-25g | Creative Biolabs | 25 µg | EUR 1013 |
|
Description: Biotinylated Human ITGA4&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P13612-1 (ITGA4)&P05556-1 (ITGB1)) |
|||
Biotinylated Human ITGA5&ITGB1 Heterodimer Protein (Phe 42-Tyr 995 (ITGA5)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1623Lsx-200g | Creative Biolabs | 200 µg | EUR 3844 |
|
Description: Biotinylated Human ITGA5&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P08648-1 (ITGA5)&P05556-1 (ITGB1)) |
|||
Biotinylated Human ITGA5&ITGB1 Heterodimer Protein (Phe 42-Tyr 995 (ITGA5)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1623Lsx-25g | Creative Biolabs | 25 µg | EUR 1013 |
|
Description: Biotinylated Human ITGA5&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P08648-1 (ITGA5)&P05556-1 (ITGB1)) |
|||
Biotinylated Human ITGA8&ITGB1 Heterodimer Protein (Phe 39-Leu 1012 (ITGA8)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1624Lsx-200g | Creative Biolabs | 200 µg | EUR 3844 |
|
Description: Biotinylated Human ITGA8&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P53708-1 (ITGA8)&P05556-1 (ITGB1)) |
|||
Biotinylated Human ITGA8&ITGB1 Heterodimer Protein (Phe 39-Leu 1012 (ITGA8)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1624Lsx-25g | Creative Biolabs | 25 µg | EUR 1013 |
|
Description: Biotinylated Human ITGA8&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P53708-1 (ITGA8)&P05556-1 (ITGB1)) |
|||
Biotinylated Human ITGAV&ITGB1 Heterodimer Protein (Phe 31-Val 992 (ITGAV)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1625Lsx-200g | Creative Biolabs | 200 µg | EUR 3844 |
|
Description: Biotinylated Human ITGAV&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: NP_002201.1 (ITGAV)&P05556-1 (ITGB1)) |
|||
Biotinylated Human ITGAV&ITGB1 Heterodimer Protein (Phe 31-Val 992 (ITGAV)&Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1625Lsx-25g | Creative Biolabs | 25 µg | EUR 1013 |
|
Description: Biotinylated Human ITGAV&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: NP_002201.1 (ITGAV)&P05556-1 (ITGB1)) |
|||
Human ITGA6&ITGB1 Heterodimer Protein (Phe 24-Gly 1012 (ITGA6) and Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1845Lsx-100g | Creative Biolabs | 100 µg | EUR 1178 |
|
Description: Human ITGA6&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P23229-2 (ITGA6)&P05556-1 (ITGB1)) |
|||
Human ITGA6&ITGB1 Heterodimer Protein (Phe 24-Gly 1012 (ITGA6) and Gln 21-Asp 728 (ITGB1)) |
|||
| VAng-1845Lsx-1mg | Creative Biolabs | 1 mg | EUR 7969 |
|
Description: Human ITGA6&ITGB1 Heterodimer protein, expressed in human 293 cells. (Uniprot ID: P23229-2 (ITGA6)&P05556-1 (ITGB1)) |
|||
Recombinant Mouse Fibroblast Growth Factor-21, His Tag |
|||
| 7-00391 | CHI Scientific | 2µg | Ask for price |
Recombinant Mouse Fibroblast Growth Factor-21, His Tag |
|||
| 7-00392 | CHI Scientific | 10µg | Ask for price |
Recombinant Mouse Fibroblast Growth Factor-21, His Tag |
|||
| 7-00393 | CHI Scientific | 1mg | Ask for price |
Histidine-tag (poly-His/Hisx6) Protein (His-tag-fusion protein) ELISA Kit, 96 tests, Quantitative |
|||
| 800-440-HIS | Alpha Diagnostics | 1 kit | EUR 895 |
Recombinant (E.Coli, His-tag) Human Ubiquitin Conjugating enzyme 7, His-tag |
|||
| RP-425 | Alpha Diagnostics | 10 ug | EUR 225 |
Recombinant E.coli LACTB Protein, His, E.coli-20ug |
|||
| QP12522-HIS-20ug | EnQuireBio | 20ug | EUR 201 |
Recombinant E.coli LACTB Protein, His, E.coli-5ug |
|||
| QP12522-HIS-5ug | EnQuireBio | 5ug | EUR 155 |
Itgb1/ Rat Itgb1 ELISA Kit |
|||
| ELI-07117r | Lifescience Market | 96 Tests | EUR 886 |
Recombinant (E.Coli) Human Eotaxin (CCL11), His-tag |
|||
| RP-1045 | Alpha Diagnostics | 5 ug | EUR 164 |
Recombinant (E.Coli, His-tag) Human AminoAcylase-1 |
|||
| RP-382 | Alpha Diagnostics | 10 ug | EUR 286 |
Recombinant (E.Coli, His-tag) Human Paraoxonase-1 |
|||
| RP-385 | Alpha Diagnostics | 10 ug | EUR 286 |
Recombinant (E.Coli, His-tag) Human Paraoxonase-2 |
|||
| RP-386 | Alpha Diagnostics | 10 ug | EUR 286 |
Recombinant (E.Coli, His-tag) )Human Chorionic Gonadotropin |
|||
| RP-599 | Alpha Diagnostics | 10 ug | EUR 225 |
Recombinant (E.Coli, His-tag) Human Beta-Trace |
|||
| RP-783 | Alpha Diagnostics | 10 ug | EUR 286 |
Recombinant (E.Coli, His-tag) Human L-Selectin |
|||
| RP-835 | Alpha Diagnostics | 10 ug | EUR 286 |
Recombinant (E.Coli, His-tag) Human P-Selectin |
|||
| RP-836 | Alpha Diagnostics | 10 ug | EUR 286 |
Recombinant (E.Coli, His-tag) Human Annexin 7 |
|||
| RP-890 | Alpha Diagnostics | 10 ug | EUR 286 |
Recombinant (E.Coli, His-tag) Human Annexin 9 |
|||
| RP-891 | Alpha Diagnostics | 10 ug | EUR 286 |
Recombinant (E.Coli, His-tag) Human Ephrin A1 |
|||
| RP-936 | Alpha Diagnostics | 2 ug | EUR 347 |
Recombinant (E.Coli, His-tag) Human Ephrin B1 |
|||
| RP-937 | Alpha Diagnostics | 2 ug | EUR 347 |
Recombinant (E.Coli, His-tag) Human Ephrin B3 |
|||
| RP-938 | Alpha Diagnostics | 2 ug | EUR 347 |
Recombinant (E.Coli, His-tag) Human Fyn-p59 |
|||
| RP-946 | Alpha Diagnostics | 2 ug | EUR 347 |
Recombinant (E.Coli, His-tag) Human Melanoma (gp100) |
|||
| RP-949 | Alpha Diagnostics | 2 ug | EUR 347 |
Recombinant (E.Coli, His-tag) Human Mammaglobin-A |
|||
| RP-952 | Alpha Diagnostics | 2 ug | EUR 347 |
Recombinant (E.Coli, His-tag) Human Synaptobrevin-1 |
|||
| RP-987 | Alpha Diagnostics | 20 ug | EUR 164 |
Recombinant (E.Coli, His-tag) Human Synaptobrevin-2 |
|||
| RP-988 | Alpha Diagnostics | 5 ug | EUR 164 |
Recombinant Human STYX Protein, His, E.coli-10ug |
|||
| QP13638-HIS-10ug | EnQuireBio | 10ug | EUR 201 |
Recombinant Human STYX Protein, His, E.coli-1mg |
|||
| QP13638-HIS-1mg | EnQuireBio | 1mg | EUR 5251 |
Recombinant Human STYX Protein, His, E.coli-1ug |
|||
| QP13638-HIS-1ug | EnQuireBio | 1ug | EUR 155 |
Recombinant Human STYX Protein, His, E.coli-2ug |
|||
| QP13638-HIS-2ug | EnQuireBio | 2ug | EUR 155 |
Recombinant Human STYX Protein, His, E.coli-50ug |
|||
| QP13638-HIS-50ug | EnQuireBio | 50ug | EUR 1161 |
Recombinant Human STYX Protein, His, E.coli-5ug |
|||
| QP13638-HIS-5ug | EnQuireBio | 5ug | EUR 201 |
Recombinant Human SUMO1 Protein, His, E.coli-20ug |
|||
| QP13648-HIS-20ug | EnQuireBio | 20ug | EUR 201 |
Recombinant Human SUMO1 Protein, His, E.coli-5ug |
|||
| QP13648-HIS-5ug | EnQuireBio | 5ug | EUR 155 |
Recombinant Human TACSTD2 Protein, His, E.coli-10ug |
|||
| QP13683-HIS-10ug | EnQuireBio | 10ug | EUR 201 |
Recombinant Human TACSTD2 Protein, His, E.coli-25ug |
|||
| QP13683-HIS-25ug | EnQuireBio | 25ug | EUR 201 |
Recombinant Human TACSTD2 Protein, His, E.coli-2ug |
|||
| QP13683-HIS-2ug | EnQuireBio | 2ug | EUR 155 |
Recombinant Human TACSTD2 Protein, His, E.coli-5ug |
|||
| QP13683-HIS-5ug | EnQuireBio | 5ug | EUR 155 |
Recombinant Human TDP1 Protein, His, E.coli-1mg |
|||
| QP13715-HIS-1mg | EnQuireBio | 1mg | EUR 2757 |
Recombinant Human TDP1 Protein, His, E.coli-1ug |
|||
| QP13715-HIS-1ug | EnQuireBio | 1ug | EUR 155 |
Recombinant Human TDP1 Protein, His, E.coli-20ug |
|||
| QP13715-HIS-20ug | EnQuireBio | 20ug | EUR 201 |
Recombinant Human TDP1 Protein, His, E.coli-50ug |
|||
| QP13715-HIS-50ug | EnQuireBio | 50ug | EUR 1261 |